Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0472 · 1 trial · 2 indications
DLT will be defined as any drug-related AE observed during the DLT evaluation period (e.g. Cycle 1) that results in a change to a given dose or a delay in initiating the next cycle.
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience one or more AE's will be reported.
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-0472 | EXPERIMENTAL | Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens until disease progression or withdrawal/discontinuation. |
| MK-0472 + Pembrolizumab | EXPERIMENTAL | Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens until disease progression or withdrawal/discontinuation, plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years). |
| MK-0472 + MK-1084 | EXPERIMENTAL | Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens, plus MK-1084 via oral capsule until disease progression or withdrawal/discontinuation. |
| Name | Type | Description |
|---|---|---|
| MK-0472 | DRUG | Oral Administration |
| Pembrolizumab | BIOLOGICAL | IV infusion |
| MK-1084 | DRUG | Oral Administration |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed solid tumor by pathology report that is advanced/metastatic * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have re...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MK-0472 is an investigational small molecule being developed for the treatment of metastatic solid tumors and advanced solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
MK-0472 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's potential in treating patients with advanced or metastatic solid tumors.
MK-0472 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is active but not recruiting participants, and the drug is being studied for safety and dosing in patients with advanced or metastatic solid tumors.
MK-0472 is being studied in a Phase 1 clinical trial with the identifier NCT05853367, titled "Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)." This trial is active but not recruiting, with an estimated enrollment of 95 participants across multiple countries including the United States, Canada, Chile, Israel, Poland, Spain, and Switzerland.
MK-0472 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials for the treatment of advanced or metastatic solid tumors. The drug is still in early-stage clinical development, and its safety and effectiveness have not yet been established for regulatory approval.